Cite
Coates JT, Sun S, Leshchiner I, et al. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer Discov. 2021;11(10):2436-2445doi: 10.1158/2159-8290.CD-21-0702.
Coates, J. T., Sun, S., Leshchiner, I., Thimmiah, N., Martin, E. E., McLoughlin, D., Danysh, B. P., Slowik, K., Jacobs, R. A., Rhrissorrakrai, K., Utro, F., Levovitz, C., Denault, E., Walmsley, C. S., Kambadakone, A., Stone, J. R., Isakoff, S. J., Parida, L., Juric, D., Getz, G., Bardia, A., & Ellisen, L. W. (2021). Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer discovery, 11(10), 2436-2445. https://doi.org/10.1158/2159-8290.CD-21-0702
Coates, James T, et al. "Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer." Cancer discovery vol. 11,10 (2021): 2436-2445. doi: https://doi.org/10.1158/2159-8290.CD-21-0702
Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, Danysh BP, Slowik K, Jacobs RA, Rhrissorrakrai K, Utro F, Levovitz C, Denault E, Walmsley CS, Kambadakone A, Stone JR, Isakoff SJ, Parida L, Juric D, Getz G, Bardia A, Ellisen LW. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer Discov. 2021 Oct;11(10):2436-2445. doi: 10.1158/2159-8290.CD-21-0702. Epub 2021 Aug 17. PMID: 34404686; PMCID: PMC8495771.
Copy
Download .nbib